ALFASIGMA SPA
- Country
- 🇮🇹Italy
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.alfasigma.com
Clinical Trials
42
Trial Phases
3 Phases
Drug Approvals
15
Drug Approvals
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- 国药准字HJ20171307
- Approval Date
- Jan 26, 2025
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- 国药准字HJ20171308
- Approval Date
- Jan 26, 2025
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140282
- Approval Date
- Mar 15, 2021
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140280
- Approval Date
- Mar 15, 2021
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140281
- Approval Date
- Mar 15, 2021
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- H20171308
- Approval Date
- Jun 24, 2019
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 80
- Registration Number
- NCT06865417
- Locations
- 🇧🇪
Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
🇧🇪Centre Hospitalier Regional De La Citadelle, Liege, Belgium
🇧🇪Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur, Belgium
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06222034
- Locations
- 🇫🇷
CHU Amiens - Hopital Nord, Amiens Cedex 1, France
🇫🇷Bicêtre University Hospital, Le Kremlin Bicêtre, France
🇩🇪Children's university hospital Charité, Campus Virchow, SPZ, Berlin, Germany
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 600
- Registration Number
- NCT05817942
- Locations
- 🇦🇹
LKH - Universitätsklinikum Graz, Graz, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria
🇦🇹KH der Barmherzigen Brüder St.Veit an der Glan, St. Veit an der Glan, Austria
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
- Conditions
- Axial Spondyloarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 495
- Registration Number
- NCT05785611
- Locations
- 🇧🇪
Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪ReumaClinic, Genk, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
- Conditions
- Chronic Intestinal Pseudo-obstruction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 17
- Registration Number
- NCT05724069
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
🇮🇹Policlinico S.Orsola-Malpighi, Bologna, Italy
🇮🇹Aou Arcispedale Sant'Anna Di Cona, Cona, Italy
- Prev
- 1
- 2
- 3
- 4
- Next
News
Obeticholic Acid Shows Long-Term Benefit in Primary Biliary Cholangitis
COBALT trial data, published in *The American Journal of Gastroenterology*, shows obeticholic acid (OCA) significantly reduces adverse outcomes in PBC patients.